David J. Arthur

David J. Arthur, listed as chief executive, appears in our data through filings on Salarius Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 11 February 2020 to 13 February 2023, the count stands at 20 filings.

Purchases make up the whole of the open-market record (11 purchases, €64k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 9 share grants.

The median purchase comes to €1,535. 10 out of 10 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 15 February 2023 came the latest disclosure, a share grant in Salarius Pharmaceuticals, Inc. The most recent open-market purchase was published on 31 May 2022, 1,607 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.